Dr David Lonard
Dr David Lonard is Chief Scientific Officer at CoRegen and Professor of Molecular and Cellular Biology at Baylor College of Medicine, where he co-directs the Center for Coregulator Research. He has more than 30 years of experience, with research focusing on steroid receptor coactivators, proteins involved in regulating gene expression, including SRC-3, the target of CoRegen’s lead programme.
Contact info
- Website:
- https://www.coregen.com/
ArticleTargeting SRC-3 to reprogramme regulatory T cells in cancer
Could targeting SRC-3 in regulatory T cells help overcome tumour immunosuppression? Researchers explain how this approach could restore anti-tumour immunity and what remains to be proven in patients.
ArticleSRC-3: CoRegen’s revolutionary approach to cancer
Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.